UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(X) Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the quarter ended September 30, 1996
( ) Transition Report Pursuant to Section 13 or 15 (d) of the Securities Act
of 1934
For the transition period from to
Commission File Number 1-5910
CARTER-WALLACE, INC.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
(Exact name of registrant as specified in its charter)
Delaware 13-4986583
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
1345 Avenue of the Americas
New York, New York 10105
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code: 212-339-5000
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
The number of shares of the registrant's Common Stock and Class B common stock
outstanding at September 30, 1996 were 33,964,700 and 12,426,700, respectively.
CARTER-WALLACE, INC. AND SUBSIDIARIES
INDEX TO FORM 10-Q
SEPTEMBER 30, 1996
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements
Condensed Consolidated Statements of Earnings for the
three and six months ended September 30, 1996 and 1995 1
Condensed Consolidated Balance Sheets at
September 30, 1996 and March 31, 1996 2
Condensed Consolidated Statements of Cash Flows
for the six months ended September 30, 1996 and 1995 3
Notes to Condensed Consolidated Financial Statements 4
Report by KPMG Peat Marwick LLP on their Limited Review 6
Item 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations 7
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings 11
Item 4 - Submission of Matters to a Vote of Security Holders 11
Item 6 - Exhibits and Reports on Form 8-K 11
Signatures 12
<TABLE>
PART I - FINANCIAL INFORMATION
CARTER-WALLACE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)
<CAPTION>
Three Months Ended Six Months Ended
September 30, September 30,
1996 1995 1996 1995
Revenues:
<S> <C> <C> <C> <C>
Net sales $159,532,000 $154,810,000 $329,421,000 $331,847,000
Other revenues 1,660,000 1,948,000 3,572,000 4,290,000
161,192,000 156,758,000 332,993,000 336,137,000
Cost and expenses:
Cost of goods sold 62,308,000 59,712,000 124,771,000 122,104,000
Advertising, marketing
& other selling
expenses 60,408,000 59,966,000 124,136,000 124,583,000
Research & development
expenses 6,244,000 6,536,000 12,892,000 13,357,000
General, administrative
& other expenses 21,826,000 20,778,000 44,007,000 43,958,000
Provision for
restructuring - 16,500,000 - 16,500,000
Provision for condom
plant closing - - - 20,100,000
Interest expense 913,000 935,000 1,999,000 1,744,000
151,699,000 164,427,000 307,805,000 342,346,000
Earnings (loss) before
taxes on income 9,493,000 (7,669,000) 25,188,000 (6,209,000)
Provision (benefit) for
taxes on income 3,892,000 (3,145,000) 10,327,000 (2,546,000)
Net earnings (loss) $ 5,601,000 $ (4,524,000)$ 14,861,000 $ (3,663,000)
Net earnings (loss) per
average share of common
stock outstanding $ .12 $(.10) $ .32 $(.08)
Cash dividends per share $ .04 $ .04 $ .08 $ .08
Average shares of common
stock outstanding 46,391,000 46,113,000 46,389,000 46,132,000
</TABLE>
<TABLE>
CARTER-WALLACE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
<CAPTION>
September 30, March 31,
1996 1996
Assets (Unaudited)
<S> <C> <C>
Current Assets:
Cash and cash equivalents $ 43,478,000 $ 51,185,000
Short-term investments 15,804,000 20,034,000
Accounts and other receivables
less allowances of $7,342,000
at September 30, 1996 and
$6,716,000 at March 31, 1996 129,278,000 131,931,000
Inventories:
Finished goods 52,472,000 55,427,000
Work in process 12,251,000 13,327,000
Raw materials and supplies 24,150,000 23,450,000
88,873,000 92,204,000
Deferred taxes, prepaid expenses
and other current assets 42,334,000 41,419,000
Total Current Assets 319,767,000 336,773,000
Property, plant and equipment, at cost 280,267,000 261,255,000
Less: accumulated depreciation and
amortization 128,528,000 121,982,000
151,739,000 139,273,000
Intangible assets 128,207,000 131,422,000
Deferred taxes and other assets 110,051,000 111,457,000
Total Assets $709,764,000 $718,925,000
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable $ 39,815,000 $ 38,941,000
Accrued expenses 143,385,000 154,695,000
Notes payable 3,632,000 6,054,000
Total Current Liabilities 186,832,000 199,690,000
Long-Term Liabilities:
Long-term debt 52,923,000 55,928,000
Deferred compensation 14,146,000 13,503,000
Accrued postretirement benefit obligation 69,191,000 68,588,000
Other long-term liabilities 41,472,000 48,320,000
Total Long-Term Liabilities 177,732,000 186,339,000
Stockholders' Equity:
Common stock 34,625,000 34,613,000
Class B common stock 12,580,000 12,592,000
Capital in excess of par value 3,602,000 3,268,000
Retained earnings 321,723,000 310,573,000
Less: Foreign currency translation adj.
and other 17,451,000 18,059,000
Treasury stock, at cost 9,879,000 10,091,000
Total Stockholders' Equity 345,200,000 332,896,000
Total Liabilities and Stockholders' Equity $709,764,000 $718,925,000
</TABLE>
<TABLE>
CARTER-WALLACE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
SIX MONTHS ENDED SEPTEMBER 30, 1996 AND 1995
(Unaudited)
<CAPTION>
1996 1995
Cash flows from operations:
<S> <C> <C>
Net earnings (loss) $ 14,861,000 $ (3,663,000)
Provision for one-time charges - 36,600,000
Cash payments for prior years' one-time
charges (15,138,000) (15,537,000)
Changes in assets and liabilities 6,037,000 (13,580,000)
Depreciation and amortization 11,519,000 12,753,000
17,279,000 16,573,000
Cash flows used in investing activities:
Additions to property, plant and equipment (19,944,000) (16,684,000)
Decrease (increase) in short-term
investments 4,189,000 (5,117,000)
Other investing activities 452,000 276,000
(15,303,000) (21,525,000)
Cash flows used in financing activities:
Dividends paid (3,711,000) (3,692,000)
Increase in borrowings 414,000 9,401,000
Payments of debt (6,096,000) (2,137,000)
Purchase of treasury stock (134,000) (2,815,000)
(9,527,000) 757,000
Effect of exchange rate changes on
cash and cash equivalents (156,000) 339,000
(Decrease) in cash and cash equivalents $ (7,707,000) $ (3,856,000)
</TABLE>
CARTER-WALLACE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 1996 AND 1995
Note 1: Interim Reports
The results of the interim periods are not necessarily indicative of results
expected for a full year's operations. In the opinion of management, all
adjustments necessary for a fair statement of results of these interim periods
have been reflected in these financial statements and, except as separately
disclosed herein, are of a normal recurring nature.
Note 2: Review of Independent Auditors
The financial information included in this report has been reviewed by KPMG Peat
Marwick LLP, independent auditors. A copy of their report on this limited
review is included in this Form.
Note 3: Restructuring of Operations and Facilities
In connection with its restructuring program, the Company incurred one-time
pre-tax charges of $16,500,000 in the year ended March 31, 1996 and $74,060,000
in the year ended March 31, 1995. The restructuring charges of $90,560,000
recorded over the two years consist primarily of estimated employee termination
costs ($30,800,000), estimated plant closing costs including equipment
write-offs ($26,000,000) and costs associated with the planned subleasing of off
ice space on which the Company holds a long-term lease ($27,800,000).
Included in the quarter ended September 30, 1995 is a one-time pre-tax charge
of $16,500,000 ($9,740,000 after taxes or $.21 per share) related to the
aforementioned restructuring program.
The restructuring program resulted in a worldwide reduction of approximately
990 employees, including 120 vacancies that were not filled. Through
September 30, 1996, employee termination costs of $28,000,000 have been applied
against the restructuring liability.
Net plant closing costs of $25,900,000 as well as $6,500,000 in costs associated
with the subleasing of office space on which the Company holds a long-term lease
have been applied against the restructuring liability.
Approximately $24,200,000 of the $90,560,000 provision for restructuring charges
remains to be utilized in future periods. Substantially all of the $24,200,000
represents expected future cash outlays for subleasing costs and employee
severance.
Note 4: Closure of the Trenton Condom Manufacturing Facility
In the quarter ended June 30, 1995, the Company incurred a one-time pre-tax
charge of $20,100,000 ($11,860,000 after taxes or $.26 per share) related to the
planned closure of the Company's condom manufacturing plant in Trenton, New
Jersey. Condom production performed at Trenton is in the process of being
transferred to the Company's facility in Colonial Heights, Virginia. This
pre-tax charge was subsequently adjusted by $3,000,000 to $23,100,000 in the
quarter ended March 31, 1996.
(Continued)
CARTER-WALLACE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 1996 AND 1995
(Continued)
Note 5: Felbatol
As previously reported, in the year ended March 31, 1995 the Company incurred
a one-time charge to pre-tax earnings of $37,780,000 related to use restrictions
for Felbatol. This charge was adjusted by $8,200,000 to $45,980,000 in the
quarter ended March 31, 1996. Depending on future sales levels, additional
inventory write-offs may be required. If for any reason the product at some
future date should no longer be available in the market, the Company will incur
an additional one-time charge that would have a material adverse effect on the
Company's results of operations and possibly on its financial condition. Should
the product no longer be available, the Company currently estimates that the
additional one-time charge, consisting primarily of inventory write-offs and
anticipated returns of product currently in the market, will be in the range of
$25,000,000 to $30,000,000 on a pre-tax basis.
Note 6: Litigation
Information regarding Legal Proceedings involving the Company is presented in
Note 20 "Litigation Including Environmental Matters" of the Notes to the
Consolidated Financial Statements on pages 31 to 33 of the Company's 1996 Annual
Report to Stockholders incorporated by reference in the Company's Annual Report
on Form 10-K for the fiscal year ended March 31, 1996 and is herein expressly
incorporated by reference.
In addition to the legal proceedings outlined in the Company's 1996 Annual
Report to Stockholders, eleven additional individual product liability actions
related to Felbatol have been filed against the Company. Damages are specified
in one of the actions where the complaint seeks compensatory damages of
$2,000,000. In the other actions the damages sought are unspecified.
The U.S. Court of Appeals for the Ninth Circuit has reversed and vacated the
Order of the U.S. District Court, Northern District of California, which had
certified a product liability action against the Company as a nation-wide class
action.
With respect to the action filed by New Horizons Diagnostic Corporation ("NHDC")
against Tambrands, Inc. ("Tambrands") and the Company, the parties have agreed
to a settlement which required a payment by the Company related to "stick test"
claims that was immaterial to its consolidated financial statements. The
Company has filed an action against Tambrands which, among other things, seeks
a declaratory judgment that the Company has no liability for any payments made
to NHDC with respect to the "cup test" claims.
The action filed by an alleged shareholder of the Company which purported to be
brought derivatively on behalf and for the benefit of the Company against the
directors of the Company has been dismissed by the Supreme Court of the State
and County of New York. The plaintiff has filed a notice of appeal.
The Company continues to believe, based upon opinion of counsel, that it has
good defenses to all of the above pending actions and should prevail.
<AUDIT-REPORT>
INDEPENDENT AUDITORS' REPORT
The Board of Directors
Carter-Wallace, Inc.:
We have reviewed the condensed consolidated balance sheet of Carter-Wallace,
Inc. and subsidiaries as of September 30, 1996, and the related condensed
consolidated statements of earnings for the three-month and six month periods
ended September 30, 1996 and 1995 and the condensed consolidated statements of
cash flows for the six month periods ended September 30, 1996 and 1995. These
condensed consolidated financial statements are the responsibility of the
Company's management.
We conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of interim financial
information consists principally of applying analytical procedures to financial
data, and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in
accordance with generally accepted auditing standards, the objective of which
is the expression of an opinion regarding the financial statements taken as a
whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should
be made to the condensed consolidated financial statements referred to above for
them to be in conformity with generally accepted accounting principles.
We have previously audited, in accordance with generally accepted auditing
standards, the consolidated balance sheet of Carter-Wallace, Inc. and
subsidiaries as of March 31, 1996, and the related consolidated statements of
earnings and retained earnings, and cash flows for the year then ended (not
presented herein); and in our report dated May 6, 1996, we expressed an
unqualified opinion on those consolidated financial statements. In our opinion,
the information set forth in the accompanying condensed consolidated balance
sheet as of March 31, 1996 is fairly stated, in all material respects, in
relation to the consolidated balance sheet from which it has been derived.
KPMG Peat Marwick LLP
New York, New York
October 24, 1996
</AUDIT-REPORT>
CARTER-WALLACE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Results of Operations - Three months ended September 30, 1996 compared to three
months ended September 30, 1995
Consolidated earnings after taxes in the three months ended September 30, 1996
were $5,601,000 or $.12 per share compared with a net loss of $4,524,000 or $.10
per share in the three months ended September 30, 1995. Excluding the one-time
charge for restructuring, net earnings for the three months ended September 30,
1995 were approximately $5,200,000 or $.11 per share.
Net sales increased $4,722,000 (3.1%) in the current year period as compared to
net sales in the prior year period. The higher sales level resulted primarily
from selling price increases, largely in the Health Care segment. Unit volume
was higher in both the Consumer Products and the Health Care segments. Sales
of the recently acquired BioWhittaker and Clark diagnostic product lines had a
positive effect on Health Care sales. Sales of pharmaceutical products in the
Health Care segment continue to be adversely impacted by generic competition.
Sales of Organidin NR may be particularly affected by generic competition.
Changes in foreign exchange rates had an immaterial effect on sales in the
current year period.
Other revenues, primarily interest income, decreased $288,000 from $1,948,000
in the prior year period to $1,660,000 in the current year period.
Cost of goods sold as a percentage of net sales increased from 38.6% in the
prior year period to 39.1% in the current year period primarily due to changes
in product mix.
Advertising, marketing and other selling expenses increased by $442,000 or 0.7%
versus the prior year period due to increased expenses in the Consumer Products
segment. Spending in the Health Care segment was approximately the same as in
the prior year period.
Research and development expenses decreased by $292,000 or 4.5% versus the prior
year period due to lower spending in the Health Care segment.
General, administrative and other expenses increased $1,048,000 or 5.0% versus
the prior year period, largely due to the establishment of a provision for a
trade receivable related to the bankruptcy of a pharmaceutical wholesaler.
Interest expense decreased by $22,000 from $935,000 in the prior year period to
$913,000 in the current year period.
The estimated annual effective tax rate applied in the current year period was
41%, the same rate as in the prior year period.
(Continued)
CARTER-WALLACE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Results of Operations - Six months ended September 30, 1996 compared to six
months ended September 30, 1995
Consolidated earnings after taxes in the six months ended September 30, 1996
were $14,861,000 or $.32 per share compared with a net loss of $3,663,000 or
$.08 per share in the six months ended September 30, 1995. Excluding the
one-time charges for the condom plant closing and restructuring, net earnings
for the six months ended September 30, 1995 were approximately $17,900,000 or
$.39 per share.
Net sales decreased $2,426,000 (0.7%) in the current year period as compared to
net sales in the prior year period. The lower sales level resulted primarily
from reduced unit volume in the Health Care segment. Sales of pharmaceutical
products in the Health Care segment continue to be adversely impacted by generic
competition. Sales of Organidin NR may be particularly affected by generic
competition. Sales of the recently acquired BioWhittaker and Clark diagnostic
product lines had a positive effect on Health Care sales. Unit sales were lower
overall in the Consumer Products segment; however, unit volume for Consumer
Products in international operations exceeded the prior year level.
Selling price increases, primarily in the Health Care segment, had a positive
effect on sales in comparison with the prior year period. Lower foreign
exchange rates had the effect of decreasing sales in the current year period by
approximately $300,000 versus the prior year period.
Other revenues, primarily interest income, decreased $718,000 from $4,290,000
in the prior year period to $3,572,000 in the current year period.
Cost of goods sold as a percentage of net sales increased from 36.8% in the
prior year period to 37.9% in the current year period primarily due to changes
in product mix.
Advertising, marketing and other selling expenses decreased by $447,000 or 0.4%
versus the prior year period due to reduced expenses in the Consumer Products
segment. Spending in the Health Care segment increased versus the prior year
period.
Research and development expenses decreased by $465,000 or 3.5% versus the prior
year period due to lower spending in the Health Care segment.
General, administrative and other expenses increased $49,000 or 0.1% versus the
prior year period. The increase in the current year period includes the
establishment of a provision for a trade receivable related to the bankruptcy
of a pharmaceutical wholesaler and a payment related to settlement of a patent
infringement claim, offset in part by lower rent expense and reduced
compensation including fringe benefits.
Interest expense increased by $255,000 or 14.6% over the prior year period as
a result of increased borrowings related largely to the expansion of the
Colonial Heights, VA condom facility.
The estimated annual effective tax rate applied in the current year period was
41%, the same rate as in the prior year period.
(Continued)
CARTER-WALLACE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(Continued)
Restructuring of Operations and Facilities
In connection with its restructuring program, the Company incurred one-time
pre-tax charges of $16,500,000 in the year ended March 31, 1996 and $74,060,000
in the year ended March 31, 1995. The restructuring charges of $90,560,000
recorded over the two years consist primarily of estimated employee termination
costs ($30,800,000), estimated plant closing costs including equipment
write-offs ($26,000,000) and costs associated with the planned subleasing of off
ice space on which the Company holds a long-term lease ($27,800,000).
Included in the quarter ended September 30, 1995 is a one-time pre-tax charge
of $16,500,000 ($9,740,000 after taxes or $.21 per share) related to the
aforementioned restructuring program.
The restructuring program resulted in a worldwide reduction of approximately
990 employees, including 120 vacancies that were not filled. Through
September 30, 1996, employee termination costs of $28,000,000 have been applied
against the restructuring liability.
Net plant closing costs of $25,900,000, as well as $6,500,000 in costs
associated with the subleasing of office space on which the Company holds a
long-term lease have been applied against the restructuring liability.
Approximately $24,200,000 of the $90,560,000 provision for restructuring charges
remains to be utilized in future periods. Substantially all of the $24,200,000
represents expected future cash outlays for subleasing costs and employee
severance.
Closure of the Trenton Condom Manufacturing Facility
In the quarter ended June 30, 1995, the Company incurred a one-time pre-tax
charge of $20,100,000 ($11,860,000 after taxes or $.26 per share) related to the
planned closure of the Company's condom manufacturing plant in Trenton, New
Jersey. Condom production performed at Trenton is in the process of being
transferred to the Company's facility in Colonial Heights, Virginia. This
pre-tax charge was subsequently adjusted by $3,000,000 to $23,100,000 in the
quarter ended March 31, 1996.
(Continued)
CARTER-WALLACE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(Continued)
Felbatol
As previously reported, in the year ended March 31, 1995 the Company incurred
a one-time charge to pre-tax earnings of $37,780,000 related to use restrictions
for Felbatol. This charge was adjusted by $8,200,000 to $45,980,000 in the
quarter ended March 31, 1996. Depending on future sales levels, additional
inventory write-offs may be required. If for any reason the product at some
future date should no longer be available in the market, the Company will incur
an additional one-time charge that would have a material adverse effect on the
Company's results of operations and possibly on its financial condition. Should
the product no longer be available, the Company currently estimates that the
additional one-time charge, consisting primarily of inventory write-offs and
anticipated returns of product currently in the market, will be in the range of
$25,000,000 to $30,000,000 on a pre-tax basis.
Liquidity and Capital Resources
Funds provided from operations are used for capital expenditures, acquisitions,
the purchase of treasury stock, the payment of dividends and working capital
requirements. External borrowings are incurred as needed to satisfy cash
requirements relating to seasonal business fluctuations, to finance major
facility expansion programs and to finance major acquisitions.
In the Statement of Cash Flows the positive change in assets and liabilities in
the current year period compared to that in the prior year period is due
primarily to reduced working capital requirements in the current year as well
as an increase in deferred taxes in the prior year.
Cash outlays in the six months ended September 30, 1996 relating to prior years'
one-time charges amount to $15,138,000 as compared to $15,537,000 in the prior
year.
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings
Please refer to Note 6: Litigation of Notes to Condensed Consolidated
Financial Statements for information regarding legal proceedings.
Item 4 - Submission of Matters to a Vote of Security Holders
(a) The Annual Meeting of Stockholders of the Company was held on July 16,
1996.
(b) At the Annual Meeting the following proposals were submitted to a vote
of security holders:
(1) On the resolution relating to certain attributes of individuals
to be directors of the Company, the number of votes cast in favor
of this proposal was 9,680,606 and the number of votes cast
against this proposal was 136,341,883.
(2) On the resolution relating to commissioning an independent study
of ways to increase shareholder value, the number of votes cast
in favor of this proposal was 3,228,957 and the number of votes
cast against this proposal was 142,899,976.
(3) On the resolution relating to considering ways to enhance the
value of the Company, the number of votes cast in favor of this
proposal was 3,268,146 and the number of votes cast against this
proposal was 142,875,192.
(4) On the resolution to require the Company to disclose all
political contributions made by the Company, the number of votes
cast in favor of this proposal was 1,963,441 and the number of
votes cast against this proposal was 143,767,968.
Item 6 - Exhibits and Reports on Form 8-K
(a) Exhibits - None
(b) Reports on Form 8-K - No reports on Form 8-K have been filed during
the quarter ended September 30, 1996
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Carter-Wallace, Inc.
(Registrant)
Date: October 24, 1996 /s/Daniel J. Black
Daniel J. Black
President & Chief
Operating Officer
Date: October 24, 1996 /s/Paul A. Veteri
Paul A. Veteri
Vice President, Finance
& Chief Financial Officer
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> MAR-31-1997
<PERIOD-END> SEP-30-1996
<CASH> 43,478,000
<SECURITIES> 15,804,000
<RECEIVABLES> 136,620,000
<ALLOWANCES> 7,342,000
<INVENTORY> 88,873,000
<CURRENT-ASSETS> 319,767,000
<PP&E> 280,267,000
<DEPRECIATION> 128,528,000
<TOTAL-ASSETS> 709,764,000
<CURRENT-LIABILITIES> 186,832,000
<BONDS> 56,555,000
0
0
<COMMON> 47,205,000
<OTHER-SE> 297,995,000
<TOTAL-LIABILITY-AND-EQUITY> 709,764,000
<SALES> 329,421,000
<TOTAL-REVENUES> 332,993,000
<CGS> 124,771,000
<TOTAL-COSTS> 307,805,000
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 1,999,000
<INCOME-PRETAX> 25,188,000
<INCOME-TAX> 10,327,000
<INCOME-CONTINUING> 14,861,000
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 14,861,000
<EPS-PRIMARY> .32
<EPS-DILUTED> 0
</TABLE>
